Medicaid Policy and Liver Transplant for Alcohol-Associated Liver Disease.


Journal

Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946

Informations de publication

Date de publication:
07 2020
Historique:
received: 14 08 2019
accepted: 22 10 2019
pubmed: 11 11 2019
medline: 7 5 2021
entrez: 10 11 2019
Statut: ppublish

Résumé

In some states, liver transplantation (LT) for alcohol-associated liver disease (ALD) is covered by Medicaid only with documentation of abstinence and/or alcohol rehabilitation. Different Medicaid policies may affect the distribution of LT for ALD, particularly post-2011, as centers have adopted early (i.e., specific abstinence period not required) LT practices. We surveyed Medicaid policies in all states actively performing LT and linked state policies to prospectively collected national registry data on LT recipients from 2002 to 2017 with ALD as the primary listing diagnosis. We categorized Medicaid policies for states as "restrictive" (requiring documentation of a specific abstinence period and/or rehabilitation) versus "unrestrictive" (deferring to center eligibility policies). Difference-of-differences analysis, comparing 2002-2011 versus 2012-2017, evaluated whether restrictive policies were associated with decreased proportion of LTs paid by Medicaid among patients with ALD post-2011. We performed sensitivity analyses to account for any differences by diagnosis of hepatocellular carcinoma, hepatitis C virus, nonalcoholic steatohepatitis, or Medicare insurance. We also performed a sensitivity analysis to account for any difference by prevalence of ALD among restrictive versus unrestrictive states. Of 10,836 LT recipients in 2002-2017, 7,091 were from 24 states in the restrictive group and 3,745 from 14 states in the unrestrictive group. The adjusted proportion (95% confidence interval) of LTs paid by Medicaid among restrictive versus unrestrictive states between 2002 and 2011 was 17.6% (15.4%-19.8%) versus 18.9% (15.4%-22.3%) (P = 0.54) and between 2012 and 2017, 17.2% (14.7%-19.7%) versus 23.2% (19.8%-26.6%) (P = 0.005). In difference-of-differences analysis, restrictive (versus unrestrictive) policies were associated with a 4.7% (0.8%-8.6%) (P = 0.02) absolute lower adjusted proportion of LTs for ALD paid by Medicaid post-2011. Restrictive Medicaid policies are present in most states with active LT centers and are associated with lower proportions of LTs for ALD paid by Medicaid post-2011 compared to states with unrestrictive Medicaid policies. Reevaluation of Medicaid alcohol use policies may be warranted, to align more closely with contemporary center-level practices.

Sections du résumé

BACKGROUND AND AIMS
In some states, liver transplantation (LT) for alcohol-associated liver disease (ALD) is covered by Medicaid only with documentation of abstinence and/or alcohol rehabilitation. Different Medicaid policies may affect the distribution of LT for ALD, particularly post-2011, as centers have adopted early (i.e., specific abstinence period not required) LT practices.
APPROACH AND RESULTS
We surveyed Medicaid policies in all states actively performing LT and linked state policies to prospectively collected national registry data on LT recipients from 2002 to 2017 with ALD as the primary listing diagnosis. We categorized Medicaid policies for states as "restrictive" (requiring documentation of a specific abstinence period and/or rehabilitation) versus "unrestrictive" (deferring to center eligibility policies). Difference-of-differences analysis, comparing 2002-2011 versus 2012-2017, evaluated whether restrictive policies were associated with decreased proportion of LTs paid by Medicaid among patients with ALD post-2011. We performed sensitivity analyses to account for any differences by diagnosis of hepatocellular carcinoma, hepatitis C virus, nonalcoholic steatohepatitis, or Medicare insurance. We also performed a sensitivity analysis to account for any difference by prevalence of ALD among restrictive versus unrestrictive states. Of 10,836 LT recipients in 2002-2017, 7,091 were from 24 states in the restrictive group and 3,745 from 14 states in the unrestrictive group. The adjusted proportion (95% confidence interval) of LTs paid by Medicaid among restrictive versus unrestrictive states between 2002 and 2011 was 17.6% (15.4%-19.8%) versus 18.9% (15.4%-22.3%) (P = 0.54) and between 2012 and 2017, 17.2% (14.7%-19.7%) versus 23.2% (19.8%-26.6%) (P = 0.005). In difference-of-differences analysis, restrictive (versus unrestrictive) policies were associated with a 4.7% (0.8%-8.6%) (P = 0.02) absolute lower adjusted proportion of LTs for ALD paid by Medicaid post-2011.
CONCLUSIONS
Restrictive Medicaid policies are present in most states with active LT centers and are associated with lower proportions of LTs for ALD paid by Medicaid post-2011 compared to states with unrestrictive Medicaid policies. Reevaluation of Medicaid alcohol use policies may be warranted, to align more closely with contemporary center-level practices.

Identifiants

pubmed: 31705545
doi: 10.1002/hep.31027
pmc: PMC7318101
mid: NIHMS1058775
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

130-139

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK026743
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK060414
Pays : United States

Informations de copyright

© 2019 American Association for the Study of Liver Diseases.

Références

N Engl J Med. 2011 Nov 10;365(19):1790-800
pubmed: 22070476
Am J Transplant. 2010 Oct;10(10):2305-12
pubmed: 20726963
Clin Gastroenterol Hepatol. 2018 Aug;16(8):1356-1358
pubmed: 29199144
JAMA Intern Med. 2019 Mar 1;179(3):340-348
pubmed: 30667468
Gastroenterology. 2018 Aug;155(2):422-430.e1
pubmed: 29655837
Am J Gastroenterol. 2018 Feb;113(2):175-194
pubmed: 29336434
Gastroenterology. 2018 Oct;155(4):1154-1163.e3
pubmed: 30009816
Transplantation. 2018 Mar;102(3):433-439
pubmed: 29019813
JAMA Psychiatry. 2017 Sep 1;74(9):911-923
pubmed: 28793133
Liver Transpl. 2016 Jul;22(7):895-905
pubmed: 27027394
Am J Transplant. 2016 Mar;16(3):841-9
pubmed: 26710309
JAMA Intern Med. 2019 Mar 1;179(3):348-350
pubmed: 30667460
Liver Transpl. 2005 Nov;11(11):1370-8
pubmed: 16184521
Ann Surg. 2017 Jan;265(1):20-29
pubmed: 27280501
Arch Intern Med. 2007 Jun 11;167(11):1183-8
pubmed: 17563028

Auteurs

Brian P Lee (BP)

Department of Gastroenterology, University of California, San Francisco, San Francisco, CA.

Eric Vittinghoff (E)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.

Mark J Pletcher (MJ)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.

Jennifer L Dodge (JL)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.

Norah A Terrault (NA)

Division of Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH